lymphoma

(redirected from Anaplastic large cell lymphoma)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

lymphoma,

a cancer of the tissue of the lymphatic systemlymphatic system
, network of vessels carrying lymph, or tissue-cleansing fluid, from the tissues into the veins of the circulatory system. The lymphatic system functions along with the circulatory system in absorbing nutrients from the small intestines.
..... Click the link for more information.
. There are two categories of lymphomas. One type is termed Hodgkin's diseaseHodgkin's disease,
a type of cancer of the lymphatic system. First identified in 1832 in England by Thomas Hodgkin, it is a type of malignant lymphoma. Incidence peaks in young adults and the elderly.
..... Click the link for more information.
, the other, non-Hodgkin's lymphoma (see lymphoma, non-Hodgkin'slymphoma, non-Hodgkin's,
any cancer of the lymphoid tissue (see lymphatic system) in which the Reed-Sternberg cells characteristic of Hodgkin's disease (the other category of lymphoma) are not present.
..... Click the link for more information.
). See also neoplasmneoplasm
or tumor,
tissue composed of cells that grow in an abnormal way. Normal tissue is growth-limited, i.e., cell reproduction is equal to cell death. Feedback controls limit cell division after a certain number of cells have developed, allowing for tissue repair
..... Click the link for more information.
.

lymphoma

[lim′fō·mə]
(medicine)
Any neoplasm, usually malignant, of the lymphoid tissues.
References in periodicals archive ?
Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL).
Neutrophil-rich anaplastic large cell lymphoma of T-cell lineage.
Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase 1 consortium study," Abstract 9500, American Society of Clinical Oncology, 2012 Annual Meeting.
Primary anaplastic large cell lymphoma of the lung: report of two cases and literature review.
Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.
Higher-power findings, for example recognition of the horseshoe- or kidney bean-shaped "hallmark cells" of anaplastic large cell lymphoma (ALCL), that were present in our case (Figure 2), in retrospect, could have added more insight into the tumor type prior to immunohistochemical workup.
Takeda Pharmaceutical Company Limited and Millennium: The Takeda Oncology Company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for conditional approval of brentuximab vedotin for two indications: (1) the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and (2) for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL).
The extensive investigator and corporate data presentations at ASH clearly demonstrate the important role ADCETRIS plays in the treatment of relapsed HL and systemic anaplastic large cell lymphoma and the promise of the role it potentially will play in additional future indications.
Other lymphomas in the differential diagnosis include conventional DLBCL with involvement of mediastinal lymph nodes, anaplastic large cell lymphoma (ALCL), and lymphoblastic lymphoma, especially precursor T cell-type.
Highlights include encouraging interim data from a phase II clinical trial of ADCETRIS in non-Hodgkin lymphoma and long-term follow up from a pivotal clinical trial of ADCETRIS in relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).